Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Magkouta (ATHENS, Greece), C. Kosti (ATHENS, Greece), P. Vaitsi (ATHENS, Greece), A. Pappas (ATHENS, Greece), C. Moschos (ATHENS, Greece), M. Iliopoulou (ATHENS, Greece), K. Psarra (ATHENS, Greece), I. Kalomenidis (ATHENS, Greece). Targeting of CSF1R abrogates Lewis Lung adenocarcinoma-induced malignant pleural effusion. 2861

Member's Comments

No comment yet.

Related content which might interest you: Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 Activated KRAS signaling triggers malignant pleural effusion Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015 Malignant pleural effusion cells show aberrant glucose metabolism gene expression Source: Eur Respir J 2011; 37: 1453-1465 Year: 2011 All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice Source: Eur Respir J 2009; 34: 1159-1167 Year: 2009 Early pleural fluid control is warranted to prevent reaccumulation of malignant pleural effusion in oncogene-driven lung cancer Source: International Congress 2019 – Brain Metastasis and Malignant pleural effusion: improving our understanding Year: 2019 Host-derived osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Predictive value of pro-inflammatory cytokine and pro-angiogenic factor in differentiating malignant from benign exudative effusion Source: International Congress 2014 – Diagnosis of pleural effusions and mediastinal adenopathies Year: 2014 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Non-classical monocytes potentiates the pathogenesis of malignant pleural effusion via the production of IL-1ß Source: International Congress 2019 – Biology of lung cancer Year: 2019 Mast cells recruitment to malignant pleural effusions Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010 Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 LSC Abstract – A requirement for mast cells in malignant pleural effusion Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015 Lung cancer and pleural mesothelioma Source: Eur Respir Monogr 2014; 65: 48-60 Year: 2014 Pleural effusions in lung cancer Source: Annual Congress 2012 - Clinical issues in malignant pleural effusions Year: 2012 Elevated survivin is associated with a reduced survival in patients with malignant pleural effusion Source: Annual Congress 2013 –Fundamental biology of malignant pleural effusions Year: 2013 Management of malignant pleural mesothelioma Source: ERS Skills Course 2015 Year: 2015